AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00710268
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00709553
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Food Effect Study of a Single Dose of ZD4054 (Zibotentan)
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00710047
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
An Interaction Study of Ketoconazole/Verapamil Versus AZD1305
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00707551
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
Phase 1
Completed
- Conditions
- Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT00707707
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Once-daily aclidinium/formoterolDrug: Placebo to formoterol fumarate
- First Posted Date
- 2008-06-30
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 156
- Registration Number
- NCT00706914
- Locations
- 🇺🇸
Forest Investigative Site, Milwaukee, Wisconsin, United States
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00704366
- Locations
- 🇯🇵
Research Site, Sunto-gun, Shizuoka, Japan
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
Phase 2
Completed
- Conditions
- GERDAcid Reflux DiseaseHeartburnRegurgitation
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2011-06-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 478
- Registration Number
- NCT00703534
- Locations
- 🇺🇸
Research Site, West End, Wisconsin, United States
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00703391
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 311
- Registration Number
- NCT00702325
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath